Journal of Bone and Joint Infection
Journal of Bone and Joint Infection
JBJI
Articles | Volume 4, issue 5
Articles | Volume 4, issue 5
https://doi.org/10.7150/jbji.37980
© Author(s) 2019. This work is distributed under
the Creative Commons Attribution 4.0 License.
https://doi.org/10.7150/jbji.37980
© Author(s) 2019. This work is distributed under
the Creative Commons Attribution 4.0 License.
Articles | Volume 4, issue 5
Case report
 | 
15 Oct 2019
Case report |  | 15 Oct 2019

Dalbavancin to Treat Infected Massive Endoprostheses: A Case Report and Cost Comparison Analysis

Tariq Azamgarhi, James Donaldson, Ashik Shah, and Simon Warren

Cited articles

Osmon DR, Berbari EF, Berendt AR. et al. Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guidelines by the Infectious Diseases Society of America. Clinical Infectious Diseases. 2013;56:e1–e25.
Chapman ALN, Seaton AR, Cooper AM. et al. Good practice recommendations for outpatient parenteral antimicrobial therapy (OPAT) in adults in the UK: a consensus statement. Journal of Antimicrobial Chemotherapy. 2012;67(5):1053–106.
Streit JM, Sader HS, Fritsche TR. et al. Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens. Diagn Microbiol Infect Dis. 2005;53(4):307–10.
Medicines.org.uk, Xydalba 500 mg powder for concentrate for solution for infusion. Electronic Medicines Compendium, 24 January 2019. https://www.medicines.org.uk/emc/product/2270/smpc.
Rappo U, Puttagunta S, Shevchenko V, Shevchenko A, Jandourek A, Gonzalez PL. et al. Dalbavancin for the treatment of osteomyelitis in adult patients: a randomized clinical trial of efficacy and safety. Open Forum Infect Dis. 2019;8(2):171–184. [PMC free article]
More articles (4)